JPMorgan Chase Cuts Travere Therapeutics Price Target

Analysts lower price target on biotech firm's stock to $41 from $44

Mar. 28, 2026 at 6:40am

Got story updates? Submit your updates here. ›

JPMorgan Chase & Co. has lowered its price target for Travere Therapeutics (NASDAQ:TVTX) stock to $41.00 from the previous $44.00 target. The investment bank maintained its 'overweight' rating on the biopharmaceutical company, which is focused on developing therapies for rare kidney and genetic disorders.

Why it matters

Travere Therapeutics is a key player in the rare disease drug development space, with its lead product sparsentan receiving accelerated approval from the FDA. The company's stock price and valuation are closely watched by investors as it works to bring innovative treatments to market for underserved patient populations.

The details

In its report, JPMorgan Chase cited ongoing research and development efforts at Travere Therapeutics as the reason for the lowered price target. The bank's analysts remain optimistic about the company's prospects, maintaining an 'overweight' rating on the stock despite the target price reduction.

  • JPMorgan Chase published its updated research report on Travere Therapeutics on Wednesday, March 28, 2026.

The players

JPMorgan Chase & Co.

A multinational investment bank and financial services company headquartered in New York City.

Travere Therapeutics

A biopharmaceutical company dedicated to developing and commercializing therapies for rare kidney and genetic disorders, headquartered in San Diego, California.

Got photos? Submit your photos here. ›

The takeaway

The lowered price target from JPMorgan Chase reflects the ongoing challenges and uncertainties facing Travere Therapeutics as it works to advance its pipeline of rare disease treatments. However, the bank's continued 'overweight' rating suggests it remains optimistic about the company's long-term potential.